FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too

FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too
U.S. regulators are considering extending their approval of Pfizer's rheumatoid arthritis therapy Xeljanz to ulcerative colitis as well. That possibility surfaced when the Food and Drug Administration accepted Pfizer's supplemental New Drug Application for Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe ulcerative colitis. The FDA requires a company to file a New Drug Application when it wants to market a new treatment in the United States. A supplemental application is a request to use the therapy for an additional disease. It usually includes information about the therapy's effectiveness against the other disease. That information can come from both clinical trials and pre
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *